Advances in Molecular Targeting and Immunotherapy on Angiosarcomas
10.3971/j.issn.1000-8578.2022.21.1045
- VernacularTitle:血管肉瘤的分子靶向及免疫治疗研究进展
- Author:
Lu SUN
1
;
Hongwei SHI
;
Guoliang PI
Author Information
1. Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430079, China
- Publication Type:Research Article
- Keywords:
Angiosarcoma;
Molecular targeted therapy;
Immunotherapy
- From:
Cancer Research on Prevention and Treatment
2022;49(1):62-66
- CountryChina
- Language:Chinese
-
Abstract:
Angiosarcoma(AS) is a rare malignant soft tissue sarcoma with poor differentiation and outcome originating from vascular or lymphatic endothelial cells. Currently, there is still no consensus on the treatment of AS. The chemoradiotherapy and surgical resection are the main treatment, but the curative effect is not good. With the rapid development of molecular biology, new molecular targets have been found gradually, which can benefit some patients. In addition, with the development of immunotherapy, the treatment of AS has been greatly enriched. This article expands on the progress of molecular targeting and immunotherapy of angiosarcoma and provides a reference for clinical colleagues.
